Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
0.00 (0.00%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Acer Therapeutics Inc. [ACER]
Reports for Purchase
Showing records 201 - 213 ( 213 total )
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q 2018 Financials Reported; Registry Trial Publication, EDSIVO Regulatory Filing Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q18 - Light at the End of the Tunnel for vEDS with 1H18 NDA Filing
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q and FY2017 Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
EDSIVO, a Hidden Gem in EU Soon to Enter NDA Filing in U.S.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from Our vEDS Expert Call with Dr. Pierre Boutouyrie
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Dial-in to Our KOL Call on March 6 to Learn About EDSIVO, a Hidden Gem for vEDS
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
EDSIVO Is the Answer to vEDS''s Prayers; Initiating with Buy rating
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Over-Allotment Mostly Exercised; 2018 Milestones Transformative; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
A Rapidly Emerging Orphan Drug Company in the Fast Lane; Initiating at Buy and $50 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R